Interact with experts and peers.

Recent Posts

10 of 98 Shown
  • The Promise and Challenges of Minimal Residual Disease Detection in AML

    Richard M. Stone MD - 10/20/2016
    MRD testing in AML can identify patients in CR at higher risk of relapse, but there are considerable barriers to using MRD to guide treatment.
  • How I Manage Laboratory Assay Interference With Anti-CD38 Antibodies in Myeloma

    Donna Catamero ANP-BC, OCN, CCRC - 10/17/2016
    Anti-CD38 antibodies like daratumumab can cause false-positive results on blood tests in myeloma. Do you know how to mitigate this risk?
  • Immune Checkpoint Blockade in Advanced Lung Cancer Patients: Optimizing Treatment Duration

    H. Jack West MD - 9/30/2016 1 comment / Last Comment: 10/3/2016
    How long should we continue patients with NSCLC on immune checkpoint inhibitors? H. Jack West, MD, shares his thoughts on this clinically important issue.
  • How I Treat Young, Fit Patients With Newly Diagnosed Non-del(17p) CLL

    Farrukh Awan MD, MS - 9/29/2016
    How do the latest data affect treatment selection for individual patients with newly diagnosed CLL who do not have specific genetic abnormalities?
  • Designing a New Approach to Clinical Trials in AML

    Harry P. Erba MD - 9/28/2016
    Harry P. Erba, MD, discusses the challenge of, and possible solution for, developing an effective trial for elderly patients with AML who are unfit for chemotherapy.
  • My Experiences Managing Pneumonitis and Hypophysitis in Patients Receiving Checkpoint Inhibitor Therapy

    Jeffrey S. Weber MD, PhD - 9/26/2016 10 comments / Last Comment: 10/12/2016
    Using 2 real-world clinical scenarios, this commentary focuses on practical strategies to manage pulmonary and endocrine adverse events associated with checkpoint inhibition in melanoma.
  • How I Am Using CDK4/6 Inhibitors for My Patients With Hormone Receptor–Positive MBC

    Mohammad  Jahanzeb MD, FACP - 9/21/2016 3 comments / Last Comment: 10/6/2016
    Are you considering CDK4/6 inhibitors as part of your treatment armamentarium for patients with hormone receptor–positive metastatic breast cancer? Dr. Jahanzeb provides insights from his experience.
  • How I Interpret Clinical Trial Results to Choose Salvage Immunotherapies for Adult Patients With B-Precursor ALL

    Dan Douer MD - 9/1/2016 3 comments / Last Comment: 10/3/2016
    Are you ready to use immunotherapies for your patients with relapsed/refractory ALL? Dan Douer, MD, provides his interpretation of the data and discusses the benefits and risks of different treatments.
  • How I Adapt CLL Treatment to Evolving Molecular Considerations

    Andrew D. Zelenetz MD, PhD - 8/9/2016 16 comments / Last Comment: 10/5/2016
    How should factors such as del(17q) and IgHV mutations be leveraged to individualize treatment in CLL?
  • An Interactive Online Tool Featuring Expert Recommendations for Advanced NSCLC

    David R. Gandara MD - 8/5/2016 4 comments / Last Comment: 9/4/2016
    Are you interested in seeing treatment recommendations from 5 lung cancer experts?
10 of 98 Shown
Show 10 More